Creatd, Inc. (OTCMKTS: CRTD) share value continues to drop after a brief recovery in mid-March. The firm’s stock is still not at the lowest point it has ever been, but it is not too far off at this point. The lowest that the shares have gone was $0.0457, which is the point they reached on October 11th, 2022. After that, in the final months of the previous year, the stock price shot up, reaching $1.6941 per share on November 18th.
The last time when the shares reached this height was in February 2022. However, back then, the price was rapidly spiraling down from a much higher point. Unfortunately for the company and its investors, after reaching $1.6941 in November, the share price crashed in a sharp correction, sinking to $0.50 by the end of November.
CRTD found a strong support at this level, which allowed it to bounce back up to $0.90, which is where the company encountered a strong resistance. It kept bouncing back and forth between these two levels throughout December 2022 and January 2023. However, as time passed, the fluctuations were becoming smaller, as the price seemingly started achieving greater stability. Looking back now, however, it becomes clear that the volatility may have decreased, but the overall trend became bearish somewhere in mid-January.
To Find out the inside Scoop on CRTD, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
CRTD price was dropping again, and in the second half of February, it broke the support level at $0.50, sinking to $0.16 by February 27th. After briefly recovering in early March, the price went back up to $0.3, encountering a resistance here, as well, which pushed it back down to $0.1156 this time, which was on March 14th. In the last 48 hours, the price managed to recover a bit once more, sitting at $0.15 at the time of writing.

Creatd, Inc. (OTCMKTS: CRTD) stock has seen a rough performance over the last year, with only a brief period of recovery in November 2022. Other than that, the last 12 months were marked by nothing but price crashes triggered by various events that followed the company. In recent months — specifically in December — the company announced an upcoming merge with Global Tech Industries, albeit without disclosing the terms of the deal. After that, reports said that Global Tech Industries had decided to bid $100 million in stock in order to acquire Creatd. Creatd even halted any discussions with other potential acquirers for 30 days as part of the LOI. At the time, its CEO and Chairman, Jeremy Frommer, said:
There are two elements to this merger, fundamental and technical. The opportunity to advance the Creatd business model and scale revenues coupled with the unique technical position we find our two public companies in, is a momentous opportunity. At the time of closing of any proposed transaction, GTII share delivery to Creatd shareholders will only occur in instances of registered ownership with the transfer agent or DTC.
For a time, everything was going well for the company until February 24th, when reports emerged that Creatd had terminated the proposed acquisition discussions with Global Tech. This was what triggered the stock crash, as many were disappointed that the deal did not succeed.
Around that time, the company was also struggling with a potential illegal naked short selling, and it launched CEOBLOC to try and fight it. One positive development at the time was the fact that CRTD became available on Upstream, which marked the third issuer to dual-list their shares on Upstream’s blockchain-powered market.
https://twitter.com/UpstreamXchange/status/1625520006770618368
However, the stock was hit with another blow a week ago when Creatd released an update regarding its legal dispute with The Lind Partners, LLC, and the company’s affiliates. The dispute concerns a convertible promissory note that amounts to $900,000.
For more on CRTD Subscribe Right Now!
According to Lind, Creatd breached certain representations and warranties in regard to the note. Lind demanded immediate repayment of the full amount, but Creatd instead decided to offer a number of alternatives. Lind refused to negotiate and Creatd filed a motion to dismiss. The company’s CEO said:
At this early stage, we are strictly trying to analyze data. There is more than enough evidence that there has been unusual trading in CRTD and it demands further investigation. To that end, we have asked legal counsel to look into filing multiple requests of trading records from market makers in CRTD stock. When and if the Company enters the discovery period in The Lind Partners, LLC case, any trading records related to The Lind Partners, LLC that were done with external broker dealers will also be analyzed.
Creatd, Inc. (OTCMKTS: CRTD) is a holding company that offers new economic opportunities to creators using partnerships and technology. The company’s goal is to empower creators and brands, and it claims that each of its companies shares a common mission — to create technologies and develop partnerships that would allow it to unlock new opportunities useful to entrepreneurs, brands, and creators, allowing them to also grow creatively, sustainably, as well as profitably.
For the moment, it appears that the situation is not the best for the company. It is in the middle of legal proceedings, its merger has failed, and its stock is one bad day away from reaching its all-time low. The chart above shows that CRTD is willing to grow and ready to jump on any opportunity, so the company still has a chance. Any piece of good news would likely send its stock to the path of recovery, which is why it is still worth keeping an eye on future developments. We will be updating on CRTD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CRTD.
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Sang Hyun Cho from Pixabay
Chris Lonsford
November 15, 2020 at 7:35 pm
Recent high was 2.51 not 0.51
Justin Kinney
November 15, 2020 at 7:40 pm
Thanks Longsford. Anyone else have anything to add?
joe pratt
November 15, 2020 at 10:24 pm
https://www.dropbox.com/sh/tlagm94xvkr4eah/AADYWl2TLEu9wzG5P1-nPp9ja?dl=0&preview=Cognate+PILOT+Application.pdf
By Greg Akers – Editor-in-Chief, Memphis Business Journal
Nov 13, 2020, 3:04pm CST Updated Nov 13, 2020, 3:29pm CST
A bioscience company with a large local presence is planning a new investment that would create hundreds of jobs and see three industrial sites receive major renovations and new construction.
Cognate BioServices Inc. plans to renovate three properties for “cell-therapy operations, contract development, and manufacturing for drug sponsors, and related logistics.”
The company is seeking a 15-year Jobs PILOT (payment-in-lieu-of-taxes) from the Economic Development Growth Engine (EDGE) for Memphis and Shelby County. The incentive would be worth $52 million, and be based on a $212 million project investment.
The investment would include $126 million in construction costs and $71 million in personal property. It covers sites at 4600 E. Shelby Drive, 5780 E. Shelby Drive, and 6100 Global Drive.
See ihub 330449
https://microcapdaily.wpengine.com/the-powerful-run-on-northwest-biotherapeutics-inc-otcmkts-nwbo/128611/
joseph H pratt
November 15, 2020 at 10:26 pm
ae kusterer Sunday, 11/15/20 09:24:24 PM
Re: None 0
Post #
330550
of 330554
COULD IT BE THAT NWBO WILL LICENSE THE FLASKWORKS TECHNOLOGY TO COGNATE?
https://nwbio.com/northwest-biotherapeutics-acquires-flaskworks-breakthrough-automation-technology-for-cell-therapy-products-to-enable-scale-up-of-production-volumes-and-reduction-of-production-costs/
“The Flaskworks system will follow the same batch-manufacturing process – doing so in a “closed” and automated manner.
Certain optimization work will be required so that the Flaskworks system will produce DCVax-L products with characteristics equivalent to the products made by the current DCVax-L manufacturing processes. This will then need to be confirmed by comparability studies. The Flaskworks technical team will work with NW Bio’s contract manufacturers to accomplish this. In the meantime, the Company’s DCVax products will continue to be made through the existing processes.”
https://www.dropbox.com/sh/tlagm94xvkr4eah/AADYWl2TLEu9wzG5P1-nPp9ja?dl=0&preview=Cognate+PILOT+Application.pdf
http://www.growth-engine.org/news/events/wednesday-november-18-2020-edge-board-meetings/
https://www.bizjournals.com/memphis/
KaOsiris Friday, 11/13/20 04:57:54 PM
Re: None 0
Post #
330131
of 330199
Cognate BioServices plans $212M investment in Memphis ops
Memphis Business Journal
By Greg Akers
Editor-in-Chief, Memphis Business Journal
Nov 13, 2020, 3:04pm CST
Updated 26 minutes ago